Lin, Liang
Cho, Shih-Feng
Xing, Lijie
Wen, Kenneth
Li, Yuyin
Yu, Tengteng
Hsieh, Phillip A.
Chen, Hailin http://orcid.org/0000-0003-1648-0427
Kurtoglu, Metin
Zhang, Yi
Andrew Stewart, C. http://orcid.org/0000-0001-7936-447X
Munshi, Nikhil
Anderson, Kenneth C.
Tai, Yu-Tzu http://orcid.org/0000-0001-6199-3569
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA100707, P01CA155258, RO1 CA 207237, P50 CA100707, P01CA155258, RO1 CA 050947, RO1 CA 207237)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 May 2020
Revised: 18 June 2020
Accepted: 24 June 2020
First Online: 6 July 2020
Compliance with ethical standards
:
: MK, YZ, and CAS are employees of and hold stock interest in Cartesian Therapeutics. NM serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. KCA serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no competing financial interests.